DrugPatentWatch Database Preview
Drugs in Development Information for DDP-225
Development status for investigational drug DDP-225: Patents, clinical trial progress, indications
DDP-225 is an investigational drug.
There have been 29 clinical trials for DDP-225.
The most recent clinical trial was a Phase 2 trial, which was initiated on October 1st 2014.
The most common disease conditions in clinical trials are Carcinoma, Nasopharyngeal Neoplasms, and Esophageal Neoplasms. The leading clinical trial sponsors are Sun Yat-sen University, Peking University, and First Affiliated Hospital of Guangxi Medical University.
There are twelve US patents protecting this investigational drug and one hundred and forty-one international patents.
Summary for DDP-225
| US Patents | 12 |
| International Patents | 141 |
| US Patent Applications | 17 |
| WIPO Patent Applications | 9 |
| Japanese Patent Applications | 0 |
| Clinical Trial Progress | Phase 2 (2014-10-01) |
| Vendors | 2 |
Recent Clinical Trials for DDP-225
| Title | Sponsor | Phase |
|---|---|---|
| Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）. | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Phase 2 |
| Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）. | Henan Cancer Hospital | Phase 2 |
| GP Induction Chemotherapy us TPF Adjuvant Chemotherapy Combined With DDP Concurrent Chemoradiotherapy in the Treatment of Locally Advanced NPC | Guiyang Medical University | Phase 3 |
Clinical Trial Summary for DDP-225
Top disease conditions for DDP-225
Top clinical trial sponsors for DDP-225
US Patents for DDP-225
| Drugname | Patent Number | Patent Title | Patent Assignee | Estimated Expiration |
|---|---|---|---|---|
| DDP-225 | See Pricing | Use of 4-(2-Flurophenyl)-6-methyl-2-(1-piperazinyl)thieno(2,3-D)-pyrimidin- e for treating of urinary incontinence | Arachnova Therapeutics Ltd. (Jersey, GB) | See Pricing |
| DDP-225 | See Pricing | 4-(2-Fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-D)pyrimidine in the treatment of functional bowel disorder | Dynogen Pharmaceuticals, Inc. (Waltham, MA) | See Pricing |
| DDP-225 | See Pricing | Substituted phenoxy thiazolidinediones as estrogen related receptor-.alpha. modulators | Janssen Pharmaceutica, NV (Beerse, BE) | See Pricing |
| DDP-225 | See Pricing | Substituted phenoxy N-alkylated thiazolidinediones as estrogen related receptor-.alpha. modulators | Janssen Pharmaceutica N.V. (Beerse, BE) | See Pricing |
| DDP-225 | See Pricing | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | Janssen Pharmaceutica NV (Beerse, BE) | See Pricing |
| DDP-225 | See Pricing | Substituted phenoxy thiazolidinediones as estrogen related receptor-a modulators | Janssen Pharmaceutica, NV (Beerse, BE) | See Pricing |
| DDP-225 | See Pricing | Substituted aminothiazolone indazoles as estrogen related receptor-alpha modulators | Janssen Pharmaceutica NV (Beerse, BE) | See Pricing |
| >Drugname | >Patent Number | >Patent Title | >Patent Assignee | >Estimated Expiration |
International Patents for DDP-225
| Drugname | Country | Document Number | Estimated Expiration | Related US Patent |
|---|---|---|---|---|
| DDP-225 | Austria | 397448 | 2022-01-31 | See Pricing |
| DDP-225 | Australia | 2003205836 | 2022-01-31 | See Pricing |
| DDP-225 | Brazil | 0307369 | 2022-01-31 | See Pricing |
| DDP-225 | Canada | 2474851 | 2022-01-31 | See Pricing |
| DDP-225 | China | 1279915 | 2022-01-31 | See Pricing |
| DDP-225 | China | 1625402 | 2022-01-31 | See Pricing |
| DDP-225 | Germany | 60321445 | 2022-01-31 | See Pricing |
| >Drugname | >Country | >Document Number | >Estimated Expiration | >Related US Patent |
